IDEAYA Biosciences (IDYA) News Today

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shares retraced slightly after recent gains, trading near $24.61. Over the past two days, multiple analysts have lifted price targets, reaffirmed overweight ratings and upgraded the stock, offset by downward revisions to future earnings forecasts.

• Positive Sentiment: Mizuho raised its price target on IDYA to $44 from $43 and maintained an “outperform” rating, implying roughly 78.8% upside from current levels. Article Title
• Positive Sentiment: IDYA shares jumped 5.6% on September 11th following an analyst upgrade, reflecting improved sentiment around the company’s oncology pipeline. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price objective to $38 from $36 and kept an “outperform” stance, signaling confidence in IDEAYA’s therapeutic programs. Article Title
• Positive Sentiment: Stephens reaffirmed its “overweight” rating with a $45 price objective, underlining long-term confidence in IDEAYA’s growth prospects. Article Title
• Positive Sentiment: Cantor Fitzgerald reiterated its “overweight” rating, maintaining a bullish outlook on IDEAYA’s drug development pipeline. Article Title
• Negative Sentiment: Leerink Partners cut its FY2027 EPS forecast to ($4.04) from ($3.74) and its FY2026 estimate to ($4.05) from ($3.88), indicating deeper losses ahead than the consensus estimate of ($3.07). Article Title

The mix of bullish analyst ratings and price-target raises versus the more pessimistic earnings revisions has likely contributed to the stock’s modest pullback today.